Late Pseudo-Exacerbation of Myasthenia Gravis Due to Ectopic Thymoma Invading Lower Cranial Nerves

Gregg MacLean, Alan Guberman and Antonio Giulivi

ABSTRACT: Dysarthria, dysphagia and repeated aspiration in a 54-year-old woman diagnosed and treated for myasthenia gravis 7 years earlier were initially thought to represent a late exacerbation of myasthenia. A cervical mass invading the jugular foramen and causing multiple lower cranial nerve palsies was biopsied and found to represent invasive ectopic thymoma.

RESUME: Pseudo-exacerbation tardive d'une myasthénie grave du à un thymome envahissant les nerf crâniens inférieurs Une dysarthrie, une dysphagie et des épisodes répétés d'aspiration trachéo-bronchique chez une femme âgée de 54 ans, diagnostiquée et traitée 7 ans auparavant pour une myasthénie grave ont d'abord été interprétées comme étant une exacerbation tardive de la myasthénie. Une masse cervicale envahissant le trou déchiré postérieur et causant des paralysies un niveau de plusieurs des nerfs crâniens inférieurs a été biopsiée et a été identifiée comme un thymome ectopique envahissant.


An underlying thymoma is found in 10% of cases with myasthenia gravis. As many as one-third of the thymomas may be locally invasive involving major vessels, pericardium, mediastinal pleura, lungs, lymphatics or distant hematogenous or lymphogenous metastases. Ectopic thymomas in the neck are extremely rare and when they do occur are generally located below the level of the hyoid bone.

We present a case of ectopic thymoma in a patient with myasthenia gravis which invaded the base of the skull around the jugular foramen. The resulting lower cranial nerve impairment was initially mistaken for a late exacerbation of the myasthenia.

CASE REPORT

The patient was 57 years old when she presented in late 1979 with a 1-year history of progressive fluctuating diplopia, ptosis, dysarthria, dysphagia, generalized weakness and shortness of breath. A strikingly positive Tensilon® test and a 20% to 60% decremental response to repetitive nerve stimulation at various frequencies confirmed the diagnosis of myasthenia gravis. She was built up to a dose of pyridostigmine 120 mg QID and also started on prednisone, reaching a dose of 100 mg/day. Her weakness, ocular and bulbar signs improved. She developed complications of steroid therapy including hyperglycemia, hypertension, osteoporosis, gastrointestinal bleeding and a compression fracture of T11. Prednisone was tapered to 40 mg on alternate days after 4 months. Chest x-ray and mediastinal tomograms were normal. She received a course of plasmapheresis and was admitted for thymectomy by sternal-split procedure in September 1980. Only a small amount of thyroid tissue and some microscopic thymic remnants were removed. She was discharged on prednisone 50 mg and 10 mg on alternate days and pyridostigmine 30 mg QID. Six months later she was able to stop steroids. Two years later, she was treated for an exacerbation of myasthenia gravis with plasmapheresis and then azathioprine 150 mg/day which was stopped after 10 months due to bone marrow suppression.

She remained stable on pyridostigmine 30 mg QID until January 1987 when she began to develop worsening dysphagia, hoarseness, and...
The patient was seen one year later and there was no evidence of tumor progression or worsening of her myasthenia.

Two months later a right submandibular mass was noticed and initially felt to represent a parotid tumor. Examination revealed normal facial sensation, no ptosis, bilateral mild facial weakness, normal hearing, hoarseness of voice, right palatal weakness with diminished pharyngeal sensation, mild weakness and atrophy of the right sternocleidomastoid and trapezius, striking wasting and fasciculations of the right side of the tongue.

The mass, which extended from the angle of the jaw to below the level of the carotid body was seen to be invading the base of the skull on the right near the jugular foramen on CT scanning. The tumor was debulked and submitted to a panel of 8 pathologists at the Canadian Reference Centre for Cancer Pathology. The tumor histology is shown in Figures 1-3. Epithelial cells were identified on electron microscopy and no malignant features were present. Seven of eight pathologists diagnosed ectopic thymoma and the eighth: "malignant lymphoepithelial lesion". A course of cobalt therapy followed. An MRI revealed residual tumor in the region of the jugular and hypoglossal foramina. The patient was seen one year later and there was no evidence of tumor progression or worsening of her myasthenia.

**DISCUSSION**

The thymus gland arises from ventral outgrowth of the third pharyngeal pouches which migrate to the mediastinum. Ectopic thymus tissue may be found anywhere along the path of descent but thymoma arising from undescended cervical thymus is exceedingly rare. In a review of undescended cervical thymomas in 1970, Ridenhour et al. could find only four previously reported cases in the literature in addition to their own report. We are not aware of other reported cases of clearly invasive ectopic thymoma either with or without myasthenia gravis. While there is no clear agreement on terminology and characterization of thymic histopathology, the presence or absence of invasion by thymoma has been interpreted as an indication of advancement in clinical stage. In addition to thymoma, other malignant tumors arise from the thymus gland including squamous cell carcinoma, carcinoid, lymphomas, and germ cell tumors. Malignant thymus tumors which are not associated with myasthenia gravis, may present at more advanced stages because of extensive local invasion. The clinical presentation relates to mass effect and local invasion within the mediastinum and may include dysphagia and cardiorespiratory symptoms. Most thymomas in patients with myasthenia gravis show histological features of predominantly epithelial type and gross tumor invasion is the most important factor determining prognosis. Treatment of invasive thymoma involves total resection when possible followed by radiotherapy and prednisone although adjuvant combination chemotherapy has also been effective. The role of her immunosuppressive therapy with azathioprine four years previously in the development of this unusual tumor is worthy of consideration. There is a 100-fold increased risk of neoplasia developing in renal transplant patients on immunosuppressants, especially central nervous system lymphomas and tumors of epithelial origin. Azathioprine itself has been implicated in producing an increased risk of malignancy through its immunosuppressant action. However it is doubtful that this mechanism could be implicated after a four-year interval and therefore this point is raised only for speculation.

This patient represents a very unusual case of late invasive thymoma leading to cranial nerve dysfunction in a patient with known myasthenia gravis. Late exacerbations occur in myasthenia gravis and may show features of bulbar and respiratory symptomatology. In this instance, worsening dysphagia and dysarthria could readily be distinguished from an exacerbation of myasthenia gravis on the basis of clinical examination showing unilateral lower cranial nerve dysfunction on the side of the cervical mass.

**REFERENCES**


